Core Viewpoint - The company, Olin Bio (688319.SH), is progressing towards a dual listing in Hong Kong, which could enhance its capital structure and international presence, while facing regulatory uncertainties regarding the approval process [1][2]. Stock Performance - As of February 13, 2026, Olin Bio's A-share price closed at 27.13 yuan, up 4.59%, with a trading volume of 255 million yuan and a turnover rate of 2.29% [1]. Strategic Advancement - The company aims to leverage the Hong Kong listing to accelerate its "bring in" (international patents and talent) and "go out" (global sales and technology transfer) strategies, focusing on differentiated areas such as superbug vaccines and adult vaccines [2]. - In November 2025, the company received a "satisfactory compliance" rating from the Philippines FDA, facilitating entry into the Southeast Asian market, and established a vaccine production partnership with Griffith University in Australia [2]. Project Development - The proceeds from the Hong Kong listing will be allocated to the clinical development of the rHPV (Helicobacter pylori) vaccine, expansion of the III phase clinical trials for the golden staph vaccine, and upgrades to production facilities [3]. - The restructured golden staph vaccine has completed enrollment of 6,000 cases for the III phase clinical trial, with complete data expected in the first half of 2026; the quadrivalent influenza virus split vaccine (MDCK cells) commenced its III phase clinical trial in October 2025 [3]. Future Development - The Hong Kong listing is anticipated to attract international investors, broadening financing channels, which is particularly beneficial for the long-term investment required in innovative vaccine research and development [4]. - A dual listing is expected to enhance the company's international visibility, promoting business development collaborations and expansion into overseas markets [5].

（来源：千龙网） 中信银行北京分行坚定践行国家创新驱动发展战略，突破"重抵押、重过往"的传统信贷思维，创新推出 科技成果转化贷产品，构建以技术壁垒、研发实力、市场潜力为核心的"看技术、看未来"硬科技专属评 价体系，为新质生产力培育提供精准"耐心资本"。通过主动对接企业需求，中信北分依托"1+2"快速审 批通道，为鼎持生物提供1000万元关键融资支持，持续推动金融服务向"更早、更小、更硬" 的生物科 技企业下沉，以金融活水滋养生物制药核心耗材国产化与创新动保产业升级，助力筑牢生物科技领域自 主可控产业根基。 立足国家创新驱动发展战略，紧扣未来生物产业高质量发展导向，响应生物制造自主可控与国产替代政 策要求，金融支持正成为破解生物科技领域"卡脖子"技术产业化瓶颈的关键力量。 北京鼎持生物技术有限公司是国内生物制药上游核心耗材与创新动保领域的领先企业，深耕无血清细胞 培养体系、基因工程疫苗关键技术研发，核心团队汇聚海内外生物制药领域顶尖专家与产业化资深人 才，凭借多年技术积淀，在相关领域取得重要技术进展。当下，生物制药关键原料自主可控需求迫切， 创新动保市场规模持续扩容，国产替代浪潮下行业发展潜力巨大。而企业自主研 ...

Group 1 - The core point of the article is that Hite Bio (300683) plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, effectively achieving full control [1] - This acquisition is a follow-up to a share purchase agreement signed in 2014 and aims to integrate the innovative drug research and development platform, paving the way for the commercialization of the core drug CPT (recombinant structural human tumor necrosis factor-related apoptosis-inducing ligand) [1] - The share acquisition process has taken over ten years, and this transaction marks the final stage of integration [1] Group 2 - In the past week (February 7 to 13, 2026), Hite Bio's stock price has shown a volatile downward trend, peaking at 36.03 yuan on February 10, with a single-day increase of 3.17%, but subsequently retracing to a closing price of 32.22 yuan on February 13, resulting in a cumulative decline of 3.13% over five days [2] - On February 10, the turnover rate reached 9.89%, with a trading volume of 419 million yuan, indicating active short-term trading; however, on February 12, there was a net outflow of 14.9611 million yuan from main funds, accounting for 9.75% of the total trading volume [2] - The technical analysis indicates increased volatility in the stock price, with the 20-day Bollinger Bands showing a resistance level at 35.12 yuan and a support level at 27.72 yuan [2] Group 3 - Institutional attention on Hite Bio is relatively low, with the latest sentiment being neutral; one institution predicts a net profit of 77 million yuan for 2025, representing a year-on-year increase of 283.33%, and a forecast of 339 million yuan for 2026, reflecting a year-on-year growth of 340.26%, primarily due to expectations regarding the commercialization potential of the innovative drug CPT [3] - Currently, 100% of institutional ratings are neutral, with no clear target price guidance provided [3]

来源 | 《财经》杂志 作者 | 《财经》记者 凌馨 编辑 | 王小 超跌之后的估值回归，是造就"X倍股"的最大因素 中国医药股领涨全球的2025年，涨幅最高的个股有哪些？ 香港市场，涌现出一批"三倍股""四倍股"，甚至"十倍股"，其中，有因产品海外授权交易声名鹊起的和铂医药、荣昌生物，也有2025年踩中了港股医药热点 的"打新宠儿"，还有一批，是经历了上一轮寒冬后，终于等来投资市场春天的老牌未盈利药企。 北海康成曾是"中国罕见病第一股"。它的产品，都是治疗普通人几乎没听说过的病。已经上市的两款产品，分别用于治疗黏多糖贮积症Ⅱ型、阿拉杰里综合 征以及进行性家族性胆汁淤积症。 因为主要针对罕见病市场，北海康成的产品市场都很小。2021年就在中国市场推出的首款产品，是用于治疗黏多糖贮积症Ⅱ型，至2024年末，共识别出843 名患者。另一款已上市产品，识别患者数为839名。 理论上，罕见病用药单价高，还可以享受药审、医保的各种政策倾斜，实际上，北海康成多年来仍处于亏损状态。2024年，全年收入8510.3万元，亏损金额 4.43亿元。截至2024年末，公司流动性资产4535.2万元，流动性负债4.826亿元。 北海 ...

此举紧密配合公司多款CAR-T细胞治疗产品的商业化进程，包括已上市的赛恺泽®及处于新药上市申请阶段的实体瘤 CAR-T细胞治疗产品舒瑞基奥仑赛注射液（研发代号"CT041"，拟定商品名"恺力美™"），并为多款通用型CAR-T细 胞治疗产品（如CT0596、CT1190B等）的未来量产奠定基础。在此背景下，提升符合国际标准的CAR-T细胞治疗产能 成为支撑多个产品商业化落地及增强全球竞争力的核心举措。此次交易中，本公司早期无需进行大额资本开支，有效 保留了宝贵现金流用于核心研发与市场拓展。同时，回购机制确保本公司在长期运营后可完整取得资产控制权，既维 持了生产稳定性，又强化了资产布局的灵活性。 （科济药业公众号） 2月13日，科济药业发布公告称，，公司透过其间接全资附属公司上海恺兴诊断技术有限公司，与上海市金山区湾区 高新区的重要平台企业——上海金工企业发展有限公司签署战略合作协议，总投资额不超过人民币3.7亿元，将在上海 市金山区建设先进的CAR-T细胞治疗产品商业化生产基地。 ...

Group 1 - Core viewpoint: Morgan Stanley's report indicates that WuXi Biologics (02269) has exceeded market consensus and Morgan Stanley's expectations for its 2025 performance, leading to an increase in target price from HKD 37 to HKD 51 and maintaining an "Overweight" rating [1] - Company expects full-year revenue of RMB 21.8 billion, a year-on-year increase of 16.7%, aligning with market consensus and Morgan Stanley's forecast [1] - Net profit is projected to reach RMB 4.9 billion, exceeding market consensus and Morgan Stanley's estimates by approximately 11% and 17% respectively [1] Group 2 - Morgan Stanley has raised its sales forecasts for 2025 to 2027 by 2% to 5%, and for 2028 and beyond by 6% to 9%, due to improved expectations for new order acquisition momentum [2] - The firm now predicts sales growth of 17.3% and 18.0% for 2026 and 2027 respectively [2] - Due to better-than-expected gross margin expansion, Morgan Stanley has adjusted its gross margin assumptions upward by 2 to 3 percentage points, forecasting gross margins of 46.0%, 46.2%, and 46.5% for 2025, 2026, and 2027 respectively [2]

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Investment Rating - The report maintains a "Buy" rating on the overseas education sector, specifically highlighting China Oriental Education as a key investment target [1]. Core Insights - The report indicates a positive outlook for vocational education training, with operational efficiency continuously improving. China Oriental Education is expected to achieve a net profit growth of 46% to 51% in 2025, with adjusted net profit projected between 767 million to 793 million RMB [1][7]. - The vocational training market is anticipated to benefit from an increase in high school graduates who do not enter university, leading to a significant rise in demand for vocational skills training [2][8]. - The company is implementing refined management strategies to enhance operational efficiency, expecting a gross margin increase of 5.2 percentage points to 56.5% in 2025 [3][9]. - Capital expenditures are projected to decline, with a forecast of approximately 660 million RMB in 2025, a decrease of 33.6% year-on-year, while maintaining a high dividend payout ratio [4][10]. Summary by Sections Market Overview - The education index fell by 3.2% in the week of February 6-12, underperforming the Hang Seng Index by 4.1 percentage points. Year-to-date, the education index has risen by 12.86%, outperforming the Hang Seng Index by 9.93 percentage points [6]. Company Updates - China Oriental Education has released a positive profit forecast for 2025, with an expected net profit growth of 46% to 51%, translating to an adjusted net profit of 767 million to 793 million RMB. The company anticipates a 6% increase in new training participants, driving revenue growth to between 12% and 46.1 billion RMB [7][8]. Vocational Training Demand - The vocational training sector is set to experience growth due to a mismatch in university enrollment rates and an increase in high school graduates. The number of high school graduates has risen by 2.6 million from 2021 to 2024, while university enrollment has only increased by 320,000 during the same period [2][8]. Operational Efficiency - The company is expected to continue its lean management approach from 2024, coordinating recruitment across schools to improve capacity utilization. The marketing expense ratio is projected to decrease by 2.5 percentage points to 21.2% in 2025, contributing to a net profit margin increase of 4.4 percentage points to 17.2% [3][9]. Capital Expenditure and Dividends - The company has initiated a vocational education center construction plan, with five out of six centers expected to be completed between 2023 and 2025. The capital expenditure for 2025 is estimated at 660 million RMB, with a high dividend payout ratio suggesting a dividend yield of 5.6% [4][10]. Investment Recommendations - The report recommends focusing on Hong Kong-listed vocational education companies, particularly China Oriental Education, due to its strong growth prospects and operational adjustments aimed at capturing the vocational training demand from high school graduates [13].

Group 1 - The core focus of the article is on the corporate governance of Lepu Biopharma-B (02157.HK), highlighting a proposed ten-year restricted share unit plan aimed at incentivizing and retaining employees [1] - The plan is set to be discussed at the second extraordinary general meeting scheduled for December 18, 2025 [1] - The maximum number of shares to be granted under this plan is capped at 5% of the total issued shares as of the adoption date [1]

Company Overview - The company, Vaimo Biotechnology (Zhejiang) Co., Ltd., focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [4] - Established in 2016, the company has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [4] Core Products - VVN461 (High Dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [4][6] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [4][9] Clinical Development - VVN461 has shown comparable anti-inflammatory efficacy to corticosteroids in head-to-head Phase II trials, with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) [7] - VVN001 demonstrated higher efficacy and safety compared to the standard treatment cyclosporine A (CsA) in clinical trials, improving patient experience and compliance [10] Financial Information - For the nine months ending September 30, 2024, the company reported other income and gains of approximately RMB 8.572 million, with research and development expenses of about RMB 128.261 million [11] - The company incurred losses of approximately RMB 201.535 million for the fiscal year ending 2024 [12] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected compound annual growth rate (CAGR) of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [13] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8% [16]